VTH44

VTH44 is a preclinical-stage drug candidate developed by Verra Therapeutics. It is a peptide-based small protein derived from the company's proprietary platform, which focuses on developing modified native peptide inhibitors to treat chronic diseases. While Verra Therapeutics has disclosed specific indications for other pipeline assets—such as VTH245 for COPD and VTH144 for post-myocardial infarction recovery—the specific therapeutic target and primary disease indication for VTH44 have not yet been publicly disclosed. The drug is part of a broader effort to leverage small protein therapeutics for conditions with high unmet medical needs.